» Articles » PMID: 34725176

Functional Disability to Evaluate the Risk of Arthritis in First-degree Relatives of Patients With Rheumatoid Arthritis

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2021 Nov 2
PMID 34725176
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The events that occur prior to the onset of rheumatoid arthritis (RA) continue to be delineated. We examined the relationship between self-reported joint symptoms, functional disability, and anticitrullinated protein antibody (ACPA) status in a cohort of first-degree relatives (FDR) of patients with RA who are at risk of future disease development.

Methods: We studied a cohort of 279 FDR of First Nations (FN) patients with RA who are at increased risk for future RA development, and analyzed data collected at their enrollment study visit. In parallel, we analyzed data from 279 FN subjects with no family history of RA. A subset of FDR developed inflammatory arthritis and we analyzed longitudinal data in this group.

Results: The prevalence of joint symptoms and functional disability was higher in FDR compared to non-FDR (all < 0.001). Difficulty walking (37.3% vs 18.0%) and modified Health Assessment Questionnaire (HAQ) results were higher in ACPA-positive FDR compared to ACPA-negative FDR, and HAQ was independently associated with ACPA seropositivity (OR 2.79, 95% CI 1.56-5.00). Longitudinally, in individuals who developed ACPA-positive RA, ACPA level and HAQ score were significantly associated ( = 0.45, < 0.001) in the preclinical period.

Conclusion: Compared to population-based controls, FDR have a high burden of joint symptoms and functional disability. Functional disability was most closely associated with ACPA seropositivity in the FDR, suggesting a direct role for ACPA outside of the context of clinically detectable synovitis. HAQ appears to be particularly valuable in the assessment of individuals at risk for future RA development.

Citing Articles

Lipoxygenase-derived oxylipins are enriched in anti-citrullinated protein antibody (ACPA)-positive individuals at risk for developing rheumatoid arthritis.

ONeil L, Anaparti V, Winter T, Smolik I, Meng X, Aukema H Arthritis Res Ther. 2024; 26(1):51.

PMID: 38360827 PMC: 10868017. DOI: 10.1186/s13075-024-03274-0.


Predictive risk factors before the onset of familial rheumatoid arthritis: the Tatarstan cohort study.

Arleevskaya M, Larionova R, Shagimardanova E, Gogoleva N, Kravtsova O, Novikov A Front Med (Lausanne). 2023; 10:1227786.

PMID: 37877020 PMC: 10593450. DOI: 10.3389/fmed.2023.1227786.


Modifiable risk factors linked to the development of rheumatoid arthritis: evidence, immunological mechanisms and prevention.

Maisha J, El-Gabalawy H, ONeil L Front Immunol. 2023; 14:1221125.

PMID: 37767100 PMC: 10520718. DOI: 10.3389/fimmu.2023.1221125.


Increased frequency of TIGIT+ CD4 T Cell subset in autoantibody-positive first-degree relatives of patients with rheumatoid arthritis.

Anaparti V, Tanner S, Zhang C, ONeil L, Smolik I, Meng X Front Immunol. 2022; 13:932627.

PMID: 35967356 PMC: 9366176. DOI: 10.3389/fimmu.2022.932627.


Promising role of polymeric nanoparticles in the treatment of rheumatoid arthritis.

Siddique R, Mehmood M, Haris M, Saleem A, Chaudhry Z Inflammopharmacology. 2022; 30(4):1207-1218.

PMID: 35524837 DOI: 10.1007/s10787-022-00997-x.